Novo Nordisk Pharmatech A/S — Credit Rating and Financial Key Figures

Novo Nordisk Pharmatech A/S (CVR number: 13246149) is a company from KØGE. The company reported a net sales of 1041.6 mDKK in 2025, demonstrating a growth of 8.9 % compared to the previous year. The operating profit percentage was at 10.6 % (EBIT: 110 mDKK), while net earnings were 113.9 mDKK. The profitability of the company measured by Return on Assets (ROA) was 5.8 %, which can be considered decent and Return on Equity (ROE) was 6 %, which can be considered decent. The equity ratio, a key indicator for solidity, stood at 78.5 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. Novo Nordisk Pharmatech A/S's liquidity measured by quick ratio was 1.9 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.